-
市场
-
产品
-
资讯
-
Moo社区
-
课堂
-
查看更多
-
功能介绍
-
费用费用透明,无最低余额限制
投资选择、功能介绍、费用相关信息由Moomoo Financial Inc.提供
- English
- 中文繁體
- 中文简体
- 深色
- 浅色
Myomo, Enzo Biochem And These 2 Stocks Under $2 Insiders Are Aggressively Buying
Myomo, Enzo Biochem And These 2 Stocks Under $2 Insiders Are Aggressively Buying
The Dow Jones closed lower by more than 600 points on Wednesday. When insiders purchase or sell shares, it indicates their confidence or concern around the company's prospects. Investors and traders interested in penny stocks can consider this a factor in their overall investment or trading decision.
Below is a look at a few recent notable insider transactions for penny stocks. For more, check out Benzinga's insider transactions platform.
Enzo Biochem
- The Trade: Enzo Biochem, Inc. (NYSE:ENZ) 10% owner James G Wolf bought a total of 303,000 shares at an average price of $2.47. To acquire these shares, it cost around $749.4 thousand.
- What's Happening: Enzo Biochem has been granted U.S. patent number 11,554,111 Titled "Sphingosine Pathway Modulating Compounds For The Treatment Of Coronavirus Infection."
- What Enzo Biochem Does: Enzo Biochem Inc is a bioscience company. The firm manufactures, develops and sell their proprietary solutions and platforms to clinical laboratories, specialty clinics and researchers and physicians internationally.
Xos
- The Trade: Xos, Inc. (NASDAQ:XOS) Director George N Mattson acquired a total of 128,666 shares at an average price of $0.98. The insider spent around $126.38 thousand to buy those shares.
- What's Happening: The company's stock jumped 69% over the past month.
- What Xos Does: Xos Inc is an electric mobility company. It designs and develops fully electric battery mobility systems specifically for commercial fleets.
Check This Out: Top Real Estate Stocks That May Rally
Myomo
- The Trade: Myomo, Inc. (NYSE:MYO) CEO Paul R Gudonis acquired a total of 307,692 shares at an average price of $0.33. To acquire these shares, it cost around $100 thousand.
- What's Happening: Myomo recently priced its $6.5 million public offering at $0.325 per share.
- What Myomo Does: Myomo Inc is a medical robotics company. It develops, designs, and produces myoelectric orthotics for people with neuromuscular disorders.
Don't forget to check out our premarket coverage here
Context Therapeutics
- The Trade: Context Therapeutics Inc. (NASDAQ:CNTX) CEO Martin Lehr acquired a total of 6,783 shares at an average price of $0.74. The insider spent $5 thousand to buy those shares.
- What's Happening: Context Therapeutics and Lonza recently announced that the companies are collaborating to manufacture CTIM-76, Context's clinical development candidate.
- What Context Therapeutics Does: Context Therapeutics Inc is a clinical-stage biopharmaceutical company dedicated to improving the lives of women living with cancer.
The Dow Jones closed lower by more than 600 points on Wednesday. When insiders purchase or sell shares, it indicates their confidence or concern around the company's prospects. Investors and traders interested in penny stocks can consider this a factor in their overall investment or trading decision.
道琼斯指数周三收盘下跌了600多点。当内部人士购买或出售股票时,这表明他们对公司前景的信心或担忧。对细价股感兴趣的投资者和交易者可以将其视为影响其整体投资或交易决策的一个因素。
Below is a look at a few recent notable insider transactions for penny stocks. For more, check out Benzinga's insider transactions platform.
以下是近期一些值得注意的细价股内幕交易。欲了解更多,请查看 本辛加的内幕交易 平台。
Enzo Biochem
恩佐生物化学
- The Trade: Enzo Biochem, Inc. (NYSE:ENZ) 10% owner James G Wolf bought a total of 303,000 shares at an average price of $2.47. To acquire these shares, it cost around $749.4 thousand.
- What's Happening: Enzo Biochem has been granted U.S. patent number 11,554,111 Titled "Sphingosine Pathway Modulating Compounds For The Treatment Of Coronavirus Infection."
- What Enzo Biochem Does: Enzo Biochem Inc is a bioscience company. The firm manufactures, develops and sell their proprietary solutions and platforms to clinical laboratories, specialty clinics and researchers and physicians internationally.
- 交易: Enzo Biochem, Inc. (纽约证券交易所代码:ENZ)10% 的所有者 James G Wolf 共购买了 30.3 万股股票 平均价格为2.47美元。收购这些股票的成本约为74.94万美元。
- 发生了什么: Enzo Biochem已获得美国专利号11,554,111,标题为 “用于治疗冠状病毒感染的鞘氨醇途径调节化合物”。
- 恩佐生物化学是做什么的: Enzo Biochem Inc是一家生物科学公司。该公司制造、开发其专有解决方案和平台,并将其出售给国际临床实验室、专科诊所以及研究人员和医生。
Xos
Xos
- The Trade: Xos, Inc. (NASDAQ:XOS) Director George N Mattson acquired a total of 128,666 shares at an average price of $0.98. The insider spent around $126.38 thousand to buy those shares.
- What's Happening: The company's stock jumped 69% over the past month.
- What Xos Does: Xos Inc is an electric mobility company. It designs and develops fully electric battery mobility systems specifically for commercial fleets.
- 这笔交易: Xos, Inc. (纳斯达克股票代码:XOS)导演乔治 N 马特森 共收购了 128,666 股股票 平均价格为0.98美元。知情人士花费了约126.38万美元购买这些股票。
- 发生了什么:该公司的股票在过去一个月中上涨了69%。
- Xos 在做什么: Xos Inc 是一家电动汽车公司。它专门为商用车队设计和开发全电动电池出行系统。
Check This Out: Top Real Estate Stocks That May Rally
看看这个: 可能上涨的顶级房地产股
Myomo
Myomo
- The Trade: Myomo, Inc. (NYSE:MYO) CEO Paul R Gudonis acquired a total of 307,692 shares at an average price of $0.33. To acquire these shares, it cost around $100 thousand.
- What's Happening: Myomo recently priced its $6.5 million public offering at $0.325 per share.
- What Myomo Does: Myomo Inc is a medical robotics company. It develops, designs, and produces myoelectric orthotics for people with neuromuscular disorders.
- 这笔交易: Myomo, Inc. (纽约证券交易所代码:MYO)首席执行官保罗·古多尼斯 共收购了 307,692 股股票 平均价格为0.33美元。要收购这些股票,大约需要花费10万美元。
- 发生了什么:Myomo最近将其650万美元的公开发行定价为每股0.325美元。
- Myomo 在做什么: Myomo Inc 是一家医疗机器人公司。它为神经肌肉疾病患者开发、设计和生产肌电矫形器。
Don't forget to check out our premarket coverage here
别忘了在这里查看我们的上市前报道
Context Therapeutics
情境疗法
- The Trade: Context Therapeutics Inc. (NASDAQ:CNTX) CEO Martin Lehr acquired a total of 6,783 shares at an average price of $0.74. The insider spent $5 thousand to buy those shares.
- What's Happening: Context Therapeutics and Lonza recently announced that the companies are collaborating to manufacture CTIM-76, Context's clinical development candidate.
- What Context Therapeutics Does: Context Therapeutics Inc is a clinical-stage biopharmaceutical company dedicated to improving the lives of women living with cancer.
- 这笔交易: Context Therape 纳斯达克股票代码:CNTX)首席执行官马丁·莱尔 共收购了6,783股股票 平均价格为0.74美元。知情人花了5万美元购买了这些股票。
- 发生了什么: Context Therapeutics和Lonza最近宣布,两家公司正在合作生产Context的临床开发候选药物 CTIM-76。
- 情境疗法是做什么的: Context Therapeutics Inc是一家处于临床阶段的生物制药公司,致力于改善癌症女性的生活。
moomoo是Moomoo Technologies Inc.公司提供的金融信息和交易应用程序。
在美国,moomoo上的投资产品和服务由Moomoo Financial Inc.提供,一家受美国证券交易委员会(SEC)监管的持牌主体。 Moomoo Financial Inc.是金融业监管局(FINRA)和证券投资者保护公司(SIPC)的成员。
在新加坡,moomoo上的投资产品和服务是通过Moomoo Financial Singapore Pte. Ltd.提供,该公司受新加坡金融管理局(MAS)监管(牌照号码︰CMS101000) ,持有资本市场服务牌照 (CMS) ,持有财务顾问豁免(Exempt Financial Adviser)资质。本内容未经新加坡金融管理局的审查。
在澳大利亚,moomoo上的金融产品和服务是通过Futu Securities (Australia) Ltd提供,该公司是受澳大利亚证券和投资委员会(ASIC)监管的澳大利亚金融服务许可机构(AFSL No. 224663)。请阅读并理解我们的《金融服务指南》、《条款与条件》、《隐私政策》和其他披露文件,这些文件可在我们的网站 https://www.moomoo.com/au中获取。
在加拿大,通过moomoo应用提供的仅限订单执行的券商服务由Moomoo Financial Canada Inc.提供,并受加拿大投资监管机构(CIRO)监管。
在马来西亚,moomoo上的投资产品和服务是通过Moomoo Securities Malaysia Sdn. Bhd. 提供,该公司受马来西亚证券监督委员会(SC)监管(牌照号码︰eCMSL/A0397/2024) ,持有资本市场服务牌照 (CMSL) 。本内容未经马来西亚证券监督委员会的审查。
Moomoo Technologies Inc., Moomoo Financial Inc., Moomoo Financial Singapore Pte. Ltd., Futu Securities (Australia) Ltd, Moomoo Financial Canada Inc.,和Moomoo Securities Malaysia Sdn. Bhd.是关联公司。
风险及免责提示
moomoo是Moomoo Technologies Inc.公司提供的金融信息和交易应用程序。
在美国,moomoo上的投资产品和服务由Moomoo Financial Inc.提供,一家受美国证券交易委员会(SEC)监管的持牌主体。 Moomoo Financial Inc.是金融业监管局(FINRA)和证券投资者保护公司(SIPC)的成员。
在新加坡,moomoo上的投资产品和服务是通过Moomoo Financial Singapore Pte. Ltd.提供,该公司受新加坡金融管理局(MAS)监管(牌照号码︰CMS101000) ,持有资本市场服务牌照 (CMS) ,持有财务顾问豁免(Exempt Financial Adviser)资质。本内容未经新加坡金融管理局的审查。
在澳大利亚,moomoo上的金融产品和服务是通过Futu Securities (Australia) Ltd提供,该公司是受澳大利亚证券和投资委员会(ASIC)监管的澳大利亚金融服务许可机构(AFSL No. 224663)。请阅读并理解我们的《金融服务指南》、《条款与条件》、《隐私政策》和其他披露文件,这些文件可在我们的网站 https://www.moomoo.com/au中获取。
在加拿大,通过moomoo应用提供的仅限订单执行的券商服务由Moomoo Financial Canada Inc.提供,并受加拿大投资监管机构(CIRO)监管。
在马来西亚,moomoo上的投资产品和服务是通过Moomoo Securities Malaysia Sdn. Bhd. 提供,该公司受马来西亚证券监督委员会(SC)监管(牌照号码︰eCMSL/A0397/2024) ,持有资本市场服务牌照 (CMSL) 。本内容未经马来西亚证券监督委员会的审查。
Moomoo Technologies Inc., Moomoo Financial Inc., Moomoo Financial Singapore Pte. Ltd., Futu Securities (Australia) Ltd, Moomoo Financial Canada Inc.,和Moomoo Securities Malaysia Sdn. Bhd.是关联公司。
- 分享到weixin
- 分享到qq
- 分享到facebook
- 分享到twitter
- 分享到微博
- 粘贴板
使用浏览器的分享功能,分享给你的好友吧